Somewhat Critical News Coverage Somewhat Unlikely to Impact Ocata Therapeutics (OCAT) Stock Price
Press coverage about Ocata Therapeutics (NASDAQ:OCAT) has trended somewhat negative this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ocata Therapeutics earned a media sentiment score of -0.22 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 41.420066728672 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Ocata Therapeutics (OCAT) opened at $8.47 on Friday. Ocata Therapeutics has a 12 month low of $3.06 and a 12 month high of $8.71.
About Ocata Therapeutics
Ocata Therapeutics, Inc, formerly Advanced Cell Technology, Inc, is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration.
Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.